Search Results
21 items found for "Hypomethylating agents"
- Adhesion GPCR Consortium Newsletter - May 2024
PMID: 38412860 GPR133 is hypomethylated and upregulated in decidual macrophages in recurrent spontaneous
- Discovery On Target, October 17-20, 2022, Boston, USA
technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents
- Upregulation of Phospholipase C Gene Expression Due to Norepinephrine-Induced Hypertrophic Response
(PLC) is thought to have a key role in the cardiomyocyte response to several different hypertrophic agents
- Sweet taste receptor agonists attenuate macrophage IL‐1β expression and eosinophilic inflammation...
We sought to investigate the therapeutic potential of autophagy‐enhancing agent, trehalose, or related
- GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for...
"Modulators of the G protein-coupled A2A adenosine receptor (A2AAR) have been considered promising agents
- Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated
- Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs
In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs.
- To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started from...
These insights will facilitate further development of therapeutic agents targeting the DOR.Communicated
- Genome-scale CRISPR screening reveals that C3aR signaling is critical for rapid capture of fungi...
pathogenic fungi, including Hc, the ubiquitous fungal pathogen Candida albicans, and the causative agent
- Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells...
As therapeutic options are limited, novel targets and agents for therapeutic intervention are urgently
- Applications of Cryo-EM in small molecule and biologics drug design
Structural characterization of biologics, such as vaccines, viral vectors, and gene therapy agents, has
- Coordinated transcriptomics and peptidomics of central nervous system identify neuropeptides and ...
characterization of neuropeptides and their GPCRs in G. molesta; and to develop specific neuropeptide-based agents
- An overview of the compartmentalized GPCR Signaling: Relevance and Implications
presents a barrier that restricts the passage of large molecules, making it challenging to deliver tagging agents as nanoparticles or liposomes, capable of penetrating cellular membranes and delivering the tagging agents
- Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling
enhances our understanding of class B1 GPCR biology but also opens new avenues for developing therapeutic agents
- 📰 GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
epigenetics The impact of nanobodies on GPCR structural biology and their potential as therapeutic agents
- 📰 GPCR Weekly News, March 20 to 26, 2023
GPCR Binders, Drugs, and more A snake toxin as a theranostic agent for the type 2 vasopressin receptor
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
has received Orphan Drug Designation (ODD) from the FDA for its hematopoietic stem cell mobilization agent
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
theoretically offer several advantages compared to orthosteric ligands when considered as potential therapeutic agents
- GPCR Updates: Celebrating Breakthroughs, New Course Launches Soon, and Exclusive Discounts! | Aug 26 - Sep 1, 2024
Russell to Board of Directors Adiso Announces Groundbreaking Research Highlighting ADS024 a Novel Oral Agent
- Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European ...
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency
- Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for ...
spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million grant from the Flemish Agency